Renin–angiotensin–aldosterone system (RAAS) blockade, achieved through use of ACE inhibitors and angiotensin-II receptor blockers (ARBs), can reduce systolic BP, comparable to that achieved by calcium-channel blockers (CCBs) [53] in HD patients with hypertension. This evidence concerns the gene REN and hypertensive disorder.